Accuray Incorporated (NASDAQ:ARAY) CEO Joshua Levine sold 17,093 shares of Accuray stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $4.86, for a total transaction of $83,071.98. Following the sale, the chief executive officer now owns 1,435,428 shares of the company’s stock, valued at $6,976,180.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Accuray Incorporated (ARAY) traded up $0.10 during mid-day trading on Friday, hitting $5.25. 1,641,858 shares of the company were exchanged, compared to its average volume of 713,905. The company has a quick ratio of 0.92, a current ratio of 1.48 and a debt-to-equity ratio of 2.44. Accuray Incorporated has a 52-week low of $3.60 and a 52-week high of $6.00.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. Accuray had a negative net margin of 7.49% and a negative return on equity of 55.18%. The firm had revenue of $91.00 million during the quarter, compared to analysts’ expectations of $88.26 million. During the same quarter in the previous year, the business posted ($0.12) earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. research analysts predict that Accuray Incorporated will post -0.18 EPS for the current year.

A number of equities research analysts have weighed in on ARAY shares. Zacks Investment Research upgraded shares of Accuray from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Tuesday, October 24th. Jefferies Group dropped their price target on shares of Accuray from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. Lake Street Capital initiated coverage on shares of Accuray in a report on Thursday. They issued a “buy” rating and a $10.00 price objective for the company. Cowen restated a “buy” rating and issued a $9.00 price objective on shares of Accuray in a report on Friday, October 27th. Finally, BTIG Research restated a “hold” rating on shares of Accuray in a report on Thursday, August 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $6.82.

A number of institutional investors have recently modified their holdings of the stock. Aperio Group LLC purchased a new stake in shares of Accuray during the 3rd quarter worth approximately $111,000. Goldman Sachs Group Inc. lifted its position in shares of Accuray by 116.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 30,173 shares of the medical equipment provider’s stock worth $143,000 after buying an additional 16,223 shares during the last quarter. Bank of Nova Scotia purchased a new stake in shares of Accuray during the 2nd quarter worth approximately $168,000. AHL Partners LLP lifted its position in shares of Accuray by 28.4% during the 2nd quarter. AHL Partners LLP now owns 39,823 shares of the medical equipment provider’s stock worth $189,000 after buying an additional 8,817 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Accuray during the 3rd quarter worth approximately $191,000. Institutional investors own 78.86% of the company’s stock.

WARNING: “Insider Selling: Accuray Incorporated (ARAY) CEO Sells 17,093 Shares of Stock” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/insider-selling-accuray-incorporated-aray-ceo-sells-17093-shares-of-stock.html.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.